Macrophage biology. Revealed

Developing precision medicines to modulate macrophages for the treatment of cancer.

We are passionate about the therapeutic potential of targeting macrophages for the treatment of cancer. Our vision is to develop a new approach to targeting the immunosuppressive tumour microenvironment, that exploits disease-specific macrophage biology to harness the power of the entire immune system.

Learn more

To meet this challenge, we have brought together world-leading immunologists, drug discoverers, and cancer biologists. Founded by pre-eminent scientists in the field, our unparalleled expertise guides our mission to discover new therapies that improve the long-term outcome for cancer patients.

Meet the team

We have a diversified portfolio of antibody programs progressing towards the clinic and continue to identify new therapeutic targets through our proprietary target identification approach. By combining analysis of human disease tissue, in silico data mining, and functional data from our state-of-the-art cellular models we identify and validate new drug targets in diseases where macrophages play a central role.

Learn more

Epidarex Capital is a transatlantic venture firm that invests in early-stage, high-growth life science companies in under-ventured markets. Epidarex focuses on providing risk capital and expertise to create, support, and build young companies, including spinouts, from leading research institutions in both established and emerging life science hubs.

Scottish Enterprise is Scotland’s national economic development agency and a non-departmental public body of the Scottish Government. To deliver a significant, lasting effect on the Scottish economy, we work with partners in the public and private sectors to find and exploit the best opportunities.

The University of Edinburgh is one of the world’s top universities. Our partnership with the University of Edinburgh has allowed access to intellectual property that has enabled the development and progression of our portfolio.